No Data
Sinopharm Hyundai: 2024 Annual Report
Sinopharm Hyundai: 2024 Annual Report Summary
2024 Annual Report Summary
2024 Annual Report
Shanghai Shyndec Pharmaceutical (600420.SH): Injection cefuroxime sodium has passed the consistency evaluation for generic drugs.
On March 27, Glonghui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., received the "Approval Notification for Supplementary Application for Pharmaceutical" issued by the National Medical Products Administration. This approves the injection of Cefuroxime Sodium (0.75g, 1.5g) to pass the consistency evaluation of generic drug quality and efficacy. Injection of Cefuroxime Sodium is a broad-spectrum second-generation cephalosporin, mainly used for the treatment of respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, gonorrhea, bone and joint infections caused by sensitive strains, and can also be used before or during surgery.
Shyndec Pharmaceutical Subsidiary Passes Generic Drug Consistency Evaluation for Asthma Drug
